Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ICI-induced Granulomatous Sialadenitis is Responsive to Prednisone.

medRxiv : the preprint server for health sciences·2026
Same author

Prevalence of novel Sjögren's antibodies in a multi-center cohort of dry eye patients.

The ocular surface·2025
Same author

Plain language summary: treatment of Sjögren's disease with dazodalibep.

Immunotherapy·2025
Same author

GZMK<sup>+</sup>CD8<sup>+</sup> T cells target a specific acinar cell type in Sjögren's disease.

Annals of the rheumatic diseases·2025
Same author

2023 International Rome consensus for the nomenclature of Sjögren disease.

Nature reviews. Rheumatology·2025
Same author

CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.

Nature medicine·2024
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

Noninflammatory myopathies.

Alan N Baer1, Robert L Wortmann

  • 1Division of Rheumatology, Johns Hopkins University School of Medicine, Suite 4000, Mason Lord Center Tower, 5200 Eastern Avenue, Baltimore, MD 21224, USA. alanbaer@jhmi.edu

Rheumatic Diseases Clinics of North America
|April 20, 2013
PubMed
Summary
This summary is machine-generated.

Noninflammatory myopathies can mimic autoimmune idiopathic inflammatory myopathies, presenting with weakness, pain, and exercise intolerance. This review highlights key noninflammatory conditions crucial for differential diagnosis.

Related Experiment Videos

Last Updated: May 12, 2026

Immunolabelling Myofiber Degeneration in Muscle Biopsies
06:37

Immunolabelling Myofiber Degeneration in Muscle Biopsies

Published on: December 5, 2019

Area of Science:

  • Neurology
  • Musculoskeletal Disorders
  • Immunology

Background:

  • Noninflammatory myopathies encompass a range of conditions including metabolic, toxic, infectious myopathies, and muscular dystrophies.
  • These disorders can present with clinical symptoms similar to autoimmune idiopathic inflammatory myopathies, such as muscle weakness, pain, and exercise intolerance.
  • Accurate diagnosis often necessitates specialized testing methods.

Purpose of the Study:

  • To review noninflammatory myopathies that are essential considerations in the differential diagnosis of idiopathic inflammatory myopathy.
  • To provide clinicians with a guide for distinguishing noninflammatory myopathies from autoimmune myopathies.

Main Methods:

  • Literature review focusing on noninflammatory myopathies.
  • Analysis of clinical presentations and diagnostic criteria.
  • Comparison with idiopathic inflammatory myopathies.

Main Results:

  • Identified specific metabolic, toxic, infectious myopathies, and muscular dystrophies as mimicking idiopathic inflammatory myopathies.
  • Highlighted shared symptoms like muscle weakness, pain, and exercise intolerance.
  • Emphasized the importance of specialized diagnostic techniques.

Conclusions:

  • Noninflammatory myopathies represent a critical differential diagnosis for suspected idiopathic inflammatory myopathy.
  • Awareness of these conditions and appropriate testing are vital for accurate patient management.
  • Distinguishing between inflammatory and noninflammatory myopathies ensures targeted and effective treatment strategies.